Treating Neurodegeneration by Targeting the Mechanisms of Aging

Brain aging drives devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s, which affect millions of people worldwide. Although significant resources have been invested, no approved medications can yet meaningfully alter the course of these diseases, representing an enormous unmet clinical need. Today, a deeper understanding of human aging and a growing investment interest in longevity have the potential to identify new targets and revolutionize treatment for disorders related to brain aging. In this session, moderator Kristen Fortney, PhD (CEO, BioAge Labs) will join experts in neurodegeneration biotech to discuss how approaches based on geroscience and regenerative medicine could dramatically improve treatments for AD, PD, and other conditions by targeting the fundamental mechanisms of aging. The session will be of broad interest to investors, industry, drug developers, and researchers in neurodegeneration, longevity-based therapeutics, and biotech as a whole.